USE OF OLOPAN (OLOPATADIN 0.1%) IN ALLERGIC OPTHALMOPATHOLOGY

Abstract

A statistical summary of epidemiological studies conducted by the World Health Organization (WHO) over the past 10 years has noted a global increase in the incidence of allergic diseases [1,7]. According to an official statement from the World Allergy Organization (WAO), the number of total allergens has now tripled, particularly the incidence of allergic ophthalmopathologies has increased by 25% [2,4]. Immunopathogenetic basis of allergic eye diseases is the activation of histamine receptors (H) and degranulation of mast cells [5,9,12]. The main purpose of this article is to review and analyze the existing scientific literature on olopatadine hydrochloride (Olopan 0.1% eye drop ), which is a relatively new topical antiallergic drug in ophthalmological practice, as well as to evaluate the effectiveness of Olopan drug by means of clinical research. According to the results of laboratory experimentations in rabbits, almost all conjunctival allergic symptoms (conjunctival hyperemia, tearing, swelling of the eyelids, redness and chemosis) caused by specific allergens (eg, histamine allergic mediator) were eliminated in a short time. [1,3,6,14]. In this type of animal research or animal experimentation, olopatadine hydrochloride solution has been shown to have both antihistamine and membrane cell stabilizer properties [8, 10,11].